


MARCH 2025 | EDITION #11



IB NIMBLE - a handheld app making healthcare more efficient



Updates and Accolades

Imaging Biometrics Expands Distribution Partnership with Blackford

Imaging Biometrics has strengthened its distribution agreement with Blackford by adding four advanced imaging solutions: – IB Nimble, IB ASL, IB FTB, and IB FTB Express. This expansion enables Blackford, which was acquired by Bayer in 2003, to offer these cutting-edge tools to its growing global network of clients.

IB Nimble is a mobile application that can interface with Blackford's Enterprise AI platform and is compatible with both Apple's iOS and Android mobile devices. It facilitates secure, real-time collaboration among multi-disciplinary medical experts. It is a technology of "high interest" to Blackford. [View video](#)

IB ASL is a new product offering by IB. It incorporates arterial spin labeling (ASL), a technology that can measure blood flow which is useful for treating neurological disorders including stroke. Instead of using an injected contrast agent, ASL uses the body's own blood.

Explore our exciting lineup of presentations at this year's American Society of Neuroradiology (ASNR) Annual Meeting



ASNR25

May 17-21, 2025 | Philadelphia

[Register here](#)

IB will be in Booth 320. Please schedule a time to meet with us (info@imagingbiometrics.com) or simply stop by our booth!

Don't miss the latest advancements and insights from our team!

Oral Presentations

- **POTENT IN VIVO EFFICACY OF THE NOVEL IRON MIMETIC GALLIUM MALTOLATE FOR THE TREATMENT OF PRIMARY BRAIN TUMORS**

Mona Al-Gizawiy, Robert Wujek, Kyle Johnson, Jason Sidabras, Melissa Prah, Jennifer Connelly, Christopher Chitambar, Kathleen Schmainda

- **FRACTIONAL TUMOR BURDEN ACCURATELY INFORMS SURGICAL BIOPSY TARGET**

Melissa A. Prah, Max O. Krucoff, Kathleen M. Schmainda

Electronic Poster Presentations

- **DELTA T1 (DT1) MAPS FOR THE DETERMINATION OF ABLATION EXTENT AFTER LASER INTERSTITIAL THERMAL THERAPY (LITT)**

Kathleen Schmainda, Melissa A. Prah, Felicity Giampietro, Max Krucoff

- **FRACTIONAL TUMOR BURDEN (FTB) MAPPING HELPS TO MONITOR GLIOBLASTOMA PROGRESSION IN THE CLINICAL TRIAL OF GALLIUM MALTOLATE: CASE REPORT**

Casey J. Zoss, Melissa A. Prah, Christopher R. Chitambar, MD, Jennifer M. Connelly, MD, Kathleen Schmainda, PhD

- **FRACTIONAL TUMOR BURDEN (FTB): AN EARLY PREDICTOR OF RESPONSE TO TUMOR TREATING FIELDS (TTFIELDS) IN GLIOBLASTOMA**

Kathleen M. Schmainda, Melissa A. Prah, Jennifer Connelly

- **AUTOMATED FTB MAPS: QUANTITATIVE ASSESSMENT OF BRAIN TUMOR BURDEN**

Michael Schmainda

EXPANDED ACCESS PROGRAM (EAP) UPDATE

GALLIUM MALTOLATE FOR RECURRENT GLIOBLASTOMA

We are pleased to announce the latest developments in the EAP for gallium maltolate. The EAP is designed to offer access to gallium maltolate, a novel therapeutic agent, for those who may not qualify for traditional clinical trials yet seek innovative care options.

PROGRESS IN SITE ACTIVATION

In recent months, we have made strides in expanding the program's reach through the activation of several new clinical sites across the country. Our goal is to help patients by making GaM accessible and to assess how GaM performs in real-world settings. This real-world data is essential in furthering our understanding of its therapeutic potential and in building evidence to support future FDA review processes.


ONGOING COMMITMENT TO PATIENT ACCESS

The EAP reflects our commitment to advancing treatment options for glioblastoma patients facing limited alternatives. By collaborating with leading institutions, we aim to deliver hope and support to patients and families impacted by this challenging condition.

For more details on program enrollment and site locations, please visit our website or contact us directly.

The Musella Foundation is facilitating an initiative by providing a tax-deductible donation form, enabling individuals to directly support patients in covering the costs associated with accessing gallium maltolate.

We invite you to contribute to this program by donating. Your support, regardless of the amount, will directly benefit patients with high-grade gliomas, helping them access this important treatment option. [Donate here](#)



The Lenox Hill Neurosurgery Brain Tumor Center and The Donald and Barbara Zucker School of Medicine at Hofstra / Northwell present

BRAIN TUMOR BIOTECH SUMMIT 2025

Thursday, June 5, 2025 | 9am - 1pm

Lenox Hill Hospital
 Einhorn Auditorium Entrance
 131 East 76th Street
 New York, NY 10075

Register

information

coming

soon

STRAIN FOR THE BRAIN 15TH ANNUAL RUN/WALK



WHEN:

Sun June 1, 2025

WHERE:

Harley-Davidson Museum,
 400 W Canal St
 Milwaukee, WI 53201

Imaging Biometrics proudly supports the annual Strain for the Brain event dedicated to honoring individuals diagnosed with brain tumors and those who support them. Please consider supporting this cause!


[Event registration](#)

The Lenox Hill Neurosurgery Brain Tumor Center and the Donald and Barbara Zucker School of Medicine at Hofstra / Northwell present this year's Biotech Summit. Northwell is a participant in the Imaging Biometrics sponsored Expanded Access Program. This premier event is designed to foster collaboration among colleagues to accelerate the development of new, life-saving therapies for patients with brain tumors and other CNS diseases. The event includes an Annual Gala featuring Lara Spencer, Anchor of Good Morning America, as the host and will recognize Katalin Karikó, PhD, the 2023 Nobel Prize winner in Physiology or Medicine, for her extraordinary contributions to science.

IB USER'S GROUP WEBINAR

Role of GaM as a radiosensitizer?

Watch the recording of our latest webinar exploring the potential of gallium maltolate in cancer therapy. Gain valuable insights from preclinical studies on glioblastoma and pediatric high-grade gliomas, and discover future applications, including the use of gallium as a radiosensitizer. [View here](#)



UPCOMING CONFERENCES



ISMRM Workshop on Perfusion MRI: Found in Translation

WHEN:
March 15-17, 2025,

WHERE:
Baluarte Conference Centre
Pamplona, Spain

TITLE:
Fractional Tumor Burden (FTB): A Quantitative DSC-MRI Perfusion Biomarker Predictive of Treatment Response in Glioblastoma

AUTHORS:
Kathleen M. Schmainda
Biophysics, Radiology

Melissa A. Prah
Biophysics

Jennifer Connelly
Neurology

[Register Here](#)

SPOTLIGHT



Dr. Joseph Bovi, MD, FACR

Professor of Radiation Oncology | Mobile App Developer | Tech Enthusiast
Driving Innovation at the Intersection of Medicine and Technology

Dr. Joseph A. Bovi, MD, FACR, is an adjunct professor in the Department of Radiation Oncology at the Medical College of Wisconsin. With a career spanning over two decades, Dr. Bovi's expertise in radiation oncology, particularly in the treatment of brain metastases, has earned him national recognition, with roles as a Principal Investigator on multiple clinical trials and as a leader in organizations such as NRG Oncology and ASTRO. A recipient of numerous awards, including the FACR distinction and multiple "Best Doctors in America" honors, Dr. Bovi continues to shape the future of radiation oncology through his research and clinical excellence.

Beyond his academic and clinical contributions, Dr. Bovi has been instrumental in advancing multidisciplinary care through innovative programs and technology-driven solutions. His work on hippocampal-avoidant whole-brain radiation therapy has influenced national treatment guidelines, and his leadership in the development of the NIMBLE app reflects his commitment to enhancing patient-centered care.



LOOK FOR INVITES
TO THE NEXT
USER GROUP
WEBINAR
COMING SOON

FOLLOW US ON

 https://twitter.com/iqai_ib

 <https://www.linkedin.com/company/imaging-biometrics-llc>

13416 Watertown Plank Road
Suite 260 | Elm Grove, WI 53122
+1.262.439.8252
email: info@imagingbiometrics.com